Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14102808 | 0.91 | MAPK1 (0.42) | MAPK1NPC1RAB9APOLBKDM4E | |
| SCHEMBL4894933 | 0.90 | DHODH (0.43) | MAPK1POLBKDM4ETDP1KMT2A | |
| SCHEMBL4894886 | 0.89 | NPC1 (0.43) | NPC1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL4886310 | 0.88 | ABCC1 (0.53) | RAB9APOLBKDM4EKMT2AMEN1 | |
| SCHEMBL4886327 | 0.87 | POLB (0.46) | MAPK1POLBKDM4ETDP1KMT2A | |
| SCHEMBL4886278 | 0.86 | POLB (0.38) | MAPK1NPC1RAB9APOLBKDM4E | |
| SCHEMBL4896562 | 0.85 | LMNA (0.47) | MAPK1NPC1POLBKDM4ETDP1 | |
| SCHEMBL4882718 | 0.84 | KDM4E (0.55) | MAPK1POLBKDM4ETDP1KMT2A | |
| SCHEMBL4883942 | 0.83 | POLB (0.47) | MAPK1POLBKDM4ETDP1ALDH1A1 | |
| SCHEMBL14087733 | 0.82 | POLB (0.48) | MAPK1RAB9APOLBKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | MAPK1 3579/4885NPC1 1880/4885RAB9A 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.